Faron Pharmaceuticals nominates Christine Roth and CMO Dr. Marie-Louise Fjällskog for election to its Board of Directors

– FINLAND, Turku –  Faron Pharmaceuticals Ltd. (LON: FARN | First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announced the nominations of Dr. Marie-Louise Fjällskog and Christine Roth for their elections to its Board of Directors at the forthcoming Extraordinary General Meeting on September 22, 2023.

Concurrently, Anne Whitaker will step down from the Board of Directors by the end of the EGM.

About Faron Pharmaceuticals Ltd.

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the immune system’s power. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers by targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

SOURCE: https://www.faron.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.